Industry News

New recombinant human growth hormone sustained-release microcapsules successfully developed

Views : 458
Author : BBIO
Update time : 2017-07-11 00:01:00
Recently, it was learned from the Institute of Process Engineering of the Chinese Academy of Sciences that a team led by researcher Ma Guanghui developed a recombinant human growth hormone sustained-release microcapsule with uniform particle size. The relevant results were published in the international academic journal "Molecular Pharmacy".
It is understood that recombinant human growth hormone (rhGH) is widely used in the treatment of a variety of diseases such as short stature, severe burns, and fat metabolism disorders in AIDS patients. However, rhGH has a short half-life and must be injected frequently to achieve an effective blood concentration, which results in poor patient compliance.
In response to this problem, scientists have done a lot of research on rhGH sustained-release microcapsules, but there are still widespread problems such as uneven particle size of microcapsules, inability to sustain release, and poor drug stability. At the same time, the acidic products produced by the traditional hydrophobic material microcapsules during the degradation process cause inflammation at the injection site and cause serious side reactions. Therefore, the development of safe and effective rhGH sustained-release microcapsules has important research significance.
The Ma Guanghui team first used the W/O/W double emulsion method to load rhGH into the amphiphilic material polylactic acid-polyethylene glycol copolymer emulsion, and combined with the rapid membrane emulsification technology to achieve the uniformity of the microsphere size. . Subsequent in vivo rat model experiments showed that the preparation can effectively prolong the release of rhGH in vivo, and maintain the activity of rhGH well, and the bone growth of rats is obvious, which improves the therapeutic effect. In addition, compared with the conventional polylactic acid (PLA) and polylactic acid-glycolic acid copolymer (PLGA) microcapsules, the preparation does not produce an inflammatory reaction and has no effect on major organ functions such as heart, liver and kidney, and is a kind of Safe sustained release carrier.
The research was funded by the “973” project and the National Natural Science Foundation.
Related News
CPhI Middle East & Africa CPhI Middle East & Africa
Jan .22.2020
Swisstropin & SwissHCG Bodybuilding Bio-Pharmaceutical Co.,Ltd will attend CPhI Middle East & Africa from 14 to 16 September 2020 in Abu Dhabi,UAE.
Welcome to visit our booth L60

CPhI Middle East & Africa is pharma’s regional exhibition for innovation
CPhI India 2019 CPhI India 2019
Nov .18.2019
Switzerland Bodybuilding Bio-Pharmaceutical expect to meet you in Delhi India 
NOVEMBER 26-28,2019,BOOTH NO. 2D04
CPhI & P-MEC India 2019 has closed its doors to over 45,000 visitors and upwards of 1,600 exhibitors from 44 countries, making it the large
CPhI Worldwide 2019 Frankfurt Booth 10D09 CPhI Worldwide 2019 Frankfurt Booth 10D09
Nov .06.2019
Swiss Bodybuilding attend the CPhI Worldwide 2019 from 5 to 7 November in Frankfurt,out booth number is 10D09.
Warmly welcome to visit us!

CPhI Worldwide will return for its 30th year on 5-7 November 2019 at Messe Frankfurt in Frankfurt, Germany. The